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Mycobacterial Lipids Induce Calcium Mobilization and
Degranulation of Mast Cells
To the Editor:
Tuberculosis (TB) remains the leading cause of death from a
single infectious agent, followed by HIV/AIDS (1). Emerging
countries, such as Panama, have not been able to curb TB
infection rates. The development of novel biomarkers for
diagnosis, treatment monitoring, and vaccine development is
urgently needed. The innate immune response during TB
infection is a source of biomarkers. When a susceptible host is
exposed to Mycobacterium tuberculosis, the bacteria translocate
to the mucosal barrier, interacting with a variety of immune cells,
including mast cells (MCs). The initial interaction between M.
tuberculosis and first-line defense cells induces the accumulation
and subsequent activation of these immune cells within lung
tissue, and the release of proinflammatory mediators (2).
Mycobacterial lipids appear to define the clinical fate of the
infection by modulating the immune response during TB (3).
However, the precise role of M. tuberculosis lipids in the
immunopathogenic and molecular mechanisms of MC activation
is still unknown.
MCs are abundant in the lung tissue, where they act as sentinels
for a wide variety of invading pathogens, as well as regulatory cells
during the course of acute inflammation (4). Besides specific
antigen-driven IgE crosslink stimulation, MCs can be activated by
complement components, IgG, neuropeptides, pathogen-associated
molecular patterns, mainly peptides, and whole M. tuberculosis
interaction (5). MC activation promotes the secretion of stored
proinflammatory mediators as well as de novo synthesis of
leukotrienes, platelet-activating factor, and prostaglandins.
Together with the transcription and release of cytokines and
chemokines by MCs, the host begins to make an adaptive immune
response (6).
Recently, Garcia-Rodriguez and colleagues revised our
perspective of the MC strategies used in bacterial defense and
reported interactions occurring between M. tuberculosis and
MCs (7). Shortly after exposure, MCs recognize M. tuberculosis
via the TLR2 and CD48 receptors. During this initial stage,
ESAT-6 and MPT-63 induce MC degranulation, cytokine
release, and the secretion of antimicrobial peptides such as
b-hexosaminidase and LL-37. We hypothesized that M.
tuberculosis lipid extracts are able to activate MCs. In this
preliminary study, we aimed to elucidate the role of single
phospholipids and whole-lipid extracts in MC activation. Some
results from these studies have been previously reported in the
form of an abstract (8).
Methods
Cells and culture conditions. Murine MCs from line C1.MC/C57.1
(C57 MC) were kindly provided by Dr. Stephen Galli (Stanford
University) and cultured in Dulbecco’s modified Eagle’s medium
according to standard methods (9).
M. tuberculosis lipid extracts. The bacterial lipid fractions
extracted from H37Rv M. tuberculosis, including total lipids
(T-L, NR-14837), insoluble lipids (I-L, NR-14843), soluble
lipids (S-L, NR-14842), M. leprae, phenolic glycolipid I
(PGL-I, NR-19342), and M. tuberculosis phosphatidylinositol
mannoside 6 (PIM6, NR-14847), were obtained from BEI
Resources. Purified bovine heart L-a-phosphatidylcholine (PC,
840052C) and cardiolipin (CL, 840012C) were obtained from
Avanti Polar Lipids. All M. tuberculosis lipid extracts were
resuspended according to the manufacturer’s
recommendations.
b-Hexosaminidase release and calcium mobilization assays.
C57 MCs were stimulated for 1 hour with T-L, S-L, I-L,
PC, CL, PIM6, and PGL-I lipid fractions of M. tuberculosis at
20 mg/ml each. MC degranulation was determined by measuring
b-hexosaminidase release according to a previously described
protocol (10). Ionomycin was used as a positive control. Similarly,
C57 MCs were stimulated with the above-mentioned lipids, and
intracellular calcium levels were determined using a modified
fluorimetric assay with Fluo 3-AM (Molecular Probes, Invitrogen)
for intracellular calcium labeling (10). Student’s t test was
performed for all experiments, and P values of ,0.05 were
considered significant.
Results
M. tuberculosis lipid extract fractions significantly increased MC
degranulation. b-Hexosaminidase release was measured to
assess the degranulation capacity of C57 MCs after lipid
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stimulation. The results indicated that all of the M. tuberculosis
lipid extract fractions significantly increased (P , 0.005)
b-hexosaminidase release compared with the unstimulated
control, except for PGL-I. Only the I-L and S-L M. tuberculosis
lipid extract fractions increased b-hexosaminidase release
significantly more than the ionomycin control (P , 0.005)
(Figure 1).
Soluble and insoluble M. tuberculosis lipid extract fractions
induced high levels of calcium mobilization in MCs. MCs stimulated
with 20 mg/ml of S-L and I-L M. tuberculosis lipid extract
fractions showed the highest calcium mobilization levels
(.15,000 relative fluorescence units) (Figure 2). Calcium
mobilization in MCs was also higher in response to M.
tuberculosis lipid extract fractions, including T-L, PIM6, and
PGL-I, than in response to CL and PTC lipid extract fractions
(Figure 2).
Discussion and Conclusions
Upon mucosal entry, bacteria and their lipid derivates interact
with the first line of immune defenses. Here, we investigated
the role of M. tuberculosis lipid extract fractions in MC activation.
We observed that the C57 MCs responded to mycobacterial
lipid extracts and were activated. We noted greater MC
degranulation and increasing intracellular calcium mobilization
in response to the S-L and I-L M. tuberculosis lipid extract
mixtures compared with stimulation with the T-L fraction alone.
A plausible explanation is that the M. tuberculosis S-L and I-L
extract fractions contain a wide array of lipids with greater
immunogenic properties than the T-L extract fraction stimuli.
Also, the activation after stimulation with mycobacterial lipid
extracts suggests that MCs respond specifically to M. tuberculosis
lipids. A possible explanation is that TLR2 recognizes M.
tuberculosis lipids. Further studies are warranted to describe
the response of MCs to the whole M. tuberculosis bacterium
interaction.
The mycobacterial cell envelope lipids constitute z40% of
the dry cell mass of M. tuberculosis. Their particular chemical
structure, organization, and localization at the interface between
the bacterium and the host play important roles in directing
host–pathogen interactions. A small number of well-known
M. tuberculosis antigens, such as ESAT-6, MTSA-10, and MPT-63,
have been implicated in MC activation and mediator release (5).
Our findings suggest that MCs have the potential to play an active
role in mediating the innate host response to M. tuberculosis–derived
lipid molecules. A better understanding of the interaction between
MCs and M. tuberculosis lipids could lead to the development
of new biomarkers, vaccines, or drugs against novel targets in
M. tuberculosis. n
Author disclosures are available with the text of this letter at
www.atsjournals.org.
800
%
 -
H
ex
os
am
in
id
as
e 
re
le
as
e
400
n.s.
Mycobacterium tuberculosis lipids
** ** **
**
**
**
600
200
Un
stim
ula
ted
Ion
om
icin
 (2.
5 M
)
PG
L-I
 (20
 g/
ml)
CL
 (20
 g/
ml)
PC
 (20
 g/
ml)
PIM
6 (2
0 g
/m
l)
T-L
 (20
 g/
ml)
I-L
 (20
 g/
ml)
S-L
 (20
 g/
ml)
0
Figure 1. Mycobacterium tuberculosis lipid extract fractions stimulate C57 mast cell (MC) degranulation. C57 MCs were stimulated for 60 minutes
with 20 mg/ml of total lipids (T-L), soluble lipids (S-L), insoluble lipids (I-L), phosphatidylcholine (PC), cardiolipin (CL), phosphatidylinositol
mannoside 6 (PIM6), and phenolic glycolipid I (PGL-I) lipid extract fractions from M. tuberculosis. Ionomycin was used as a positive control.
The I-L and S-L lipid extracts increased b-hexosaminidase release by 455.6% and 587.1%, respectively, which was significantly greater
(**P , 0.005) than the increase observed with the ionomycin control (55.4%). In contrast, the stimulatory effects of the T-L, PC, CL, and
PIM6 lipid extracts were considered to be significantly greater than those of the unstimulated control (**P , 0.005). The results are the average
of three independent experiments. n.s. = not significant.
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Figure 2. Mycobacterium tuberculosis lipid extract fractions induce C57 mast cell (MC) calcium mobilization. C57 MCs were stimulated
for 60 minutes with 20 mg/ml of total lipids (T-L), soluble lipids (S-L), insoluble lipids (I-L), phosphatidylcholine (PTC), cardiolipin (CL),
phosphatidylinositol mannoside 6 (PIM6), and phenolic glycolipid I (PGL-I) lipid extract fractions from M. tuberculosis. The results show calcium
mobilization levels higher than 15,000 RFU after stimulation with I-L and S-L. The results are the average of three independent experiments.
RFU = relative fluorescence units.
CORRESPONDENCE
Correspondence 815
 
10. Torres-Atencio I, Ainsua-Enrich E, de Mora F, Picado C, Martı´n M.
Prostaglandin E2 prevents hyperosmolar-induced human mast cell
activation through prostanoid receptors EP2 and EP4. PLoS One
2014;9:e110870.
Copyright © 2018 by the American Thoracic Society
More on Single-Beat Estimation of Right
Ventriculoarterial Coupling in Pulmonary
Arterial Hypertension
To the Editor:
Right ventricular (RV) function is the main determinant of
symptomatology and outcome in pulmonary arterial hypertension
(PAH) (1). However, guidelines for the diagnosis and treatment of
PAH do not advise on how best to measure RV function in these
patients (2).
It has been better realized in recent years that RV adaptation
in severe PAH is essentially homeometric, with an increase in
contractility matching the increased afterload (1). As recently
reviewed (3), the gold standard measure of RV contractility is end-
systolic elastance (Ees), which is reasonably assumed equal to
maximum elastance and defined by an end-systolic pressure (ESP)
versus end-systolic volume relationship (1, 3). To assess the
adequacy of RV contractility adaptation to afterload, Ees is
expressed relative to arterial elastance (Ea), defined by an ESP
versus stroke volume (SV) relationship (1, 3). The optimal
coupling of the RV to afterload allowing for flow output at a
minimal energy cost occurs at an Ees/Ea ratio of around 1.5 (3).
When the Ees/Ea ratio decreases to 1 or below, the homeometric
adaptation of the RV is exhausted. The RV then uses a dimensional
or “heterometric” adaptation (Starling’s law of the heart) to
maintain flow output in response to metabolic demand (3).
Because of the major prognostic relevance of RV function, there
is interest in an earlier and robust diagnosis of RV–arterial
uncoupling and definition of critical Ees and Ees/Ea values
associated with a risk for clinical deterioration. But how accurate
are these measurements as currently performed in expert PAH
centers?
Methods for assessment of RV–arterial coupling and their
prognostic value were recently reviewed in detail by Tabima
and colleagues (4). Ees can be measured from a family of
pressure–volume loops at decreasing venous return (5) or by a
single-beat method relying on the determination of a maximum
pressure from nonlinear extrapolation of early and
late isovolumic portions (before maximal and after minimal
dP/dt, respectively) of the RV pressure curve (Figure 1) (6, 7).
Ees is then equal to (maximum pressure2 ESP)/SV, and Ea is
equal to ESP/SV (3, 4).
Recent studies of RV–arterial coupling in severe PAH have
assumed that mean pulmonary artery pressure (mPAP) would be
an acceptable surrogate of ESP (3). However, this assumption is
based on measurements in a small cohort of 15 patients, none of
whom had PAH (five had pulmonary hypertension due to left heart
disease), and with ESP measured at the PAP dicrotic notch (8).
Although mPAP may be close to RV ESP in healthy individuals, the
shape of RV pressure–volume loops in patients with severe PAH
changes with increasing PAP, so that ESP becomes closer to RV
systolic pressure than to mPAP (9).
In the present study, we quantified the error associated with Ees
estimation using mPAP instead of ESP by measuring RV volumes
and pressures with a conductance catheter (4F, CD Leycom) in 20
consecutive patients with PAH. The study was approved by the
Institutional Review Board of the University of Giessen (#2015/108).
All the patients gave written informed consent. There were
13 women and 7 men, aged 516 15 years (mean 6 SD). The
diagnosis of PAH rested on a step-by-step approach to exclude
pulmonary hypertension due to cardiac or pulmonary diseases and
right heart catheterization showing mPAP .25 mm Hg and
pulmonary vascular resistance .3 Wood units, in agreement with
current recommendations (2). Results are expressed as mean 6 SD
when normally distributed (assessed by Kolmogorov-Smirnov test),
and otherwise as median (interquartile range).
Seventeen patients had idiopathic PAH, one had portal
hypertension–associated PAH, one had HIV-associated PAH,
and one had systemic sclerosis–associated PAH. On the basis of
hemodynamic measurements, pulmonary vascular resistance was
5.9 (interquartile range, 4.3–8.6) Wood units, mPAP was 416
11 mm Hg, wedged PAP was 76 2 mm Hg, and mixed venous
oxygen saturation was 696 6%. The patients were in New York
Heart Association functional class III (n = 12) or II (n = 8).
As shown in Figure 1, there was a strong correlation between
mPAP and ESP. The relationship between mPAP and ESP was
described by a linear regression model as ESP = 1.653mPAP –
7.79 (r = 0.932; r2 = 0.868; P, 0.001). However, this relationship
differed from the line of identity with underestimation of ESP by
mPAP in proportion to pulmonary hypertension severity. Pressure-
dependent bias (indicating insufficient accuracy) and large limits of
agreement (indicating insufficient precision) were confirmed on a
Bland–Altman plot (10).
The comparison of Ees, Ea, and Ees/Ea calculated using mPAP
versus ESP revealed significant differences (all P, 0.001, Wilcoxon
signed rank test): Ees was calculated as 0.876 0.44 versus 0.626
0.38 mm Hg/ml (median difference, 0.18; range, 0.03–0.56), Ea was
calculated as 0.526 0.25 versus 0.766 0.39 mm Hg/ml (median
difference, 20.18; range, 20.56 to 20.02), and Ees/Ea was
calculated as 1.846 0.78 versus 0.896 0.49 (median difference,
0.90; range, 0.20–1.85). These differences emphasize the
importance of validating different contractility measurements.
Thus, mPAP cannot be a surrogate for RV ESP in the evaluation
of RV contractility and RV–arterial coupling. Although the small
sample size of our study must be considered, our results suggest
that ESP can be cautiously estimated by the equation ESP =
1.653mPAP2 7.79 in the absence of direct measurements.
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